Skip to main content

Cullinan Therapeutics, Inc.

CGEM
Exchange
Nasdaq
Industry
Biological Products, (No Diagnostic Substances)
SEC CIK
0001789972

In the last 90 days, Cullinan Therapeutics, Inc. insiders filed 0 open-market purchases and 3 sales; 183 institutions reported holding it in 13F filings for Q2 2026, worth $1.30B in total; no superinvestor holds it.

13F holders, Q2 2022

Institutional positions in Cullinan Therapeutics, Inc. as of Jun 30, 2022. Investment managers with $100 million or more in US stocks report their long positions on Form 13F within 45 days after each quarter ends. How 13F works

Institutional holders
89
+9 vs. Q1 2022
Shares held
37.6M
+769.7K (+2.1%) vs. Q1 2022
Total value
$481.7M
+$96.1M (+24.9%) vs. Q1 2022
New holders
23
27 more added
Sold out
14
23 more reduced

2 institutions that held it in Q1 2022 haven't filed for Q2 2022 yet. Not filing isn't selling, so they aren't counted as sold out or in the changes above.

Compare with Q1 2022: new holders, sold out and not filed yet

Holders and value by quarter

Institutions reporting CGEM on Form 13F each quarter since Q1 2021, and the total value they reported. Values are as of each quarter end, so they also move with the share price.

Institutional holdersQ2 2022: 89 institutions
Q1 2021: 70 institutionsQ2 2021: 71 institutionsQ3 2021: 66 institutionsQ4 2021: 75 institutionsQ1 2022: 82 institutionsQ2 2022: 89 institutionsQ3 2022: 100 institutionsQ4 2022: 97 institutionsQ1 2023: 103 institutionsQ2 2023: 106 institutionsQ3 2023: 106 institutionsQ4 2023: 113 institutionsQ1 2024: 113 institutionsQ2 2024: 135 institutionsQ3 2024: 137 institutionsQ4 2024: 147 institutionsQ1 2025: 149 institutionsQ2 2025: 144 institutionsQ3 2025: 145 institutionsQ4 2025: 153 institutionsQ1 2026: 174 institutionsQ2 2026: 183 institutions
Value heldQ2 2022: $481.7M
Q1 2021: $1.30BQ2 2021: $828.5MQ3 2021: $762.3MQ4 2021: $559.7MQ1 2022: $386.3MQ2 2022: $481.7MQ3 2022: $474.7MQ4 2022: $397.7MQ1 2023: $329.5MQ2 2023: $397.3MQ3 2023: $344.0MQ4 2023: $375.6MQ1 2024: $670.8MQ2 2024: $1.10BQ3 2024: $1.09BQ4 2024: $798.8MQ1 2025: $489.6MQ2 2025: $471.4MQ3 2025: $362.2MQ4 2025: $653.8MQ1 2026: $931.0MQ2 2026: $1.30B
Institutions holding CGEM and their total value by quarter
QuarterHoldersValue
Q2 2026183$1.30B
Q1 2026174$931.0M
Q4 2025153$653.8M
Q3 2025145$362.2M
Q2 2025144$471.4M
Q1 2025149$489.6M
Q4 2024147$798.8M
Q3 2024137$1.09B
Q2 2024135$1.10B
Q1 2024113$670.8M
Q4 2023113$375.6M
Q3 2023106$344.0M
Q2 2023106$397.3M
Q1 2023103$329.5M
Q4 202297$397.7M
Q3 2022100$474.7M
Q2 202289$481.7M
Q1 202282$386.3M
Q4 202175$559.7M
Q3 202166$762.3M
Q2 202171$828.5M
Q1 202170$1.30B

Institutions, Q2 2022

Shares, value and share of portfolio for each institution holding Cullinan Therapeutics, Inc.; share changes are against Q1 2022.

Institutions holding CGEM in Q2 2022
InstitutionSharesValue% of portfolioChange in sharesAction
HRT Financial LP0$00.00%−14,180−100.0%Sold out
Prospera Financial Services Inc0$00.00%−1,168−100.0%Sold out
Group One Trading, L.P.0$00.00%−100−100.0%Sold out
Parametric Portfolio Associates LLC––––Not filed
Amalgamated Financial Corp.––––Not filed